IFM Investors Pty Ltd Has $3.02 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

IFM Investors Pty Ltd increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 16.5% during the first quarter, HoldingsChannel reports. The fund owned 214,041 shares of the company’s stock after acquiring an additional 30,270 shares during the quarter. IFM Investors Pty Ltd’s holdings in Teva Pharmaceutical Industries were worth $3,020,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 184,642.3% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock worth $282,656,000 after buying an additional 27,696,340 shares during the last quarter. Sound Shore Management Inc CT purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $80,791,000. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 14.4% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company’s stock worth $276,000,000 after purchasing an additional 3,413,100 shares during the period. FMR LLC increased its position in Teva Pharmaceutical Industries by 3,553.8% in the third quarter. FMR LLC now owns 2,564,339 shares of the company’s stock worth $26,156,000 after buying an additional 2,494,156 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 7.1% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock valued at $342,788,000 after buying an additional 2,188,212 shares during the period. 54.05% of the stock is owned by institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the transaction, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 390,738 shares of company stock worth $5,132,766. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.56 during mid-day trading on Friday, reaching $13.81. The company’s stock had a trading volume of 10,278,701 shares, compared to its average volume of 8,331,025. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries Limited has a 52 week low of $7.09 and a 52 week high of $14.47. The company’s fifty day moving average price is $13.51 and its two-hundred day moving average price is $11.39.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. The firm had revenue of $4.46 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on TEVA. Barclays boosted their price objective on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their price target for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. The Goldman Sachs Group upped their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.